HOME >> BIOLOGY >> NEWS
Phase III clinical program evaluates lubiprostone

BETHESDA, MD May 16, 2005 Takeda Pharmaceuticals North America (TPNA) and Sucampo Pharmaceuticals announced the initiation of a phase III clinical development program for lubiprostone in patients with constipation-predominant irritable bowel syndrome (IBS-C). Enrollment for these trials begins this month. Lubiprostone is an investigational compound currently being evaluated by the FDA for the treatment of chronic idiopathic constipation and associated pain and bloating in adults.

The IBS-C clinical development program will include two phase III trials. Each trial will examine more than 500 patients for 12 weeks to evaluate the safety and efficacy of lubiprostone.

"Irritable bowel syndrome is a condition that can impact a person's quality of life, but is currently addressed by few available therapies," said John Johanson, M.D., clinical associate professor, University of Illinois College of Medicine, and principal investigator. "Based on results from our phase II study, we believe lubiprostone may have the potential to treat IBS-C, and thus offer a new option for people living with irritable bowel syndrome."

The program includes two double-blind, randomized phase III clinical trials with a treatment period of 12 weeks, taking place at up to 130 sites around the United States. A previous phase II study in IBS-C patients evaluated the effectiveness across a range of doses. Additionally, studies of lubiprostone in chronic constipation have achieved clinical endpoints of relief of constipation and associated pain and bloating and demonstrated tolerability, regardless of gender.

Lubiprostone is a chloride channel activator, a novel compound with a unique mechanism of action. Taken orally, the agent has been shown to work locally and specifically in the GI tract by activating a specific chloride channel (CLC2). Chloride channels are proteins that carry chloride on cells lining the small intestine. When activated, these cells increase in
'"/>


16-May-2005


Page: 1 2

Related biology news :

1. Phase II study of therapeutic vaccine shows efficacy in patients with metastatic colorectal cancer
2. Biovest announces interim blinded data of fast-tracked pivotal Phase 3 clinical trial of BiovaxID
3. Oncolytics Biotech Inc. proceeds to initiate US Phase II sarcoma clinical trial
4. The Parkinsons Institute to conduct Phase III Clinical Trial of creatine for Parkinsons disease
5. Phase III trials of cellulose sulfate microbicide for HIV prevention closed
6. Phylonix awarded National Science Foundation Phase II SBIR for zebrafish screening
7. Kentucky first state to match federal SBIR-STTR Phase 1 and Phase 2 grants
8. Acorda announces positive Phase 3 Fampridine-SR study in people with multiple sclerosis
9. REMICADE Phase 3 data show rapid, significant, long-term psoriasis improvement
10. New Phase 3 data show potential benefits of Aranesp dosed every three weeks for CIA
11. Eisai announces Phase II data on E7389, a potential new therapy for the treatment of breast cancer

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:9/12/2018)... ... September 12, 2018 , ... JoVE, ... is pleased to support the professional development of academic librarians by sponsoring four ... The entrants were asked to submit successful strategies to increase collaboration among librarians ...
(Date:9/1/2018)... ... 31, 2018 , ... Right this minute, Frenchman Ben Lecomte is hard at work on his ... he’s taken on a new challenge: going from Tokyo to San Francisco, churning his limbs ... on the support boat. As the first expedition of its kind, The Swim is far ...
(Date:8/31/2018)... ... August 30, 2018 , ... USDM Life Sciences , ... sciences and healthcare industries, has received the 2018 Services Partner of the Year, Awarded ... by Box SVP of Business Development and Platform Sales, Niall Wall and received by ...
Breaking Biology News(10 mins):
(Date:8/17/2018)... ... August 16, 2018 , ... The opening of the ... acquired Chemko Technical Services in 2016. Chemko had a well established local presence, servicing ... at KSC on projects such as the ongoing work at the Mobile Launch Platform ...
(Date:8/17/2018)... , ... August 16, 2018 , ... ... announced their results from the AmbryShare project were published today in JAMA Oncology, ... the largest exome study ever conducted. , Every year hereditary breast cancer affects ...
(Date:8/14/2018)... ... ... Labconco Corporation manufactures laboratory equipment, specializing in ventilation enclosures ... other lab equipment, such as glassware washers and freeze dryers. Labconco has ISO ... and manufacturing. , Through this webinar, which is sponsored by Labconco ...
(Date:8/14/2018)... ... August 14, 2018 , ... The growing interest ... of the Chinese Association of Orthopaedic Surgeons (CAOS) held in partnership with the ... Development , Beijing, and Invibio Biomaterial Solutions partnered to demonstrate the ...
Breaking Biology Technology:
Cached News: